HESI PHARMACOLOGY
2025 LATEST TEST HESI PHARMACOLOGY (PHARM) EXAM
VERSION 1 (V1) COMPLETE ACCURATE REAL EXAM GRADED
A+ QUESTIONS AND ANSWERS
Bonie314 Stuvia
This Exam DocumentContains:
HESI PHARMACOLOGY
EXAM VERSION 1 (V1)
COMPLETE ACCURATE REAL EXAM
QUESTIONS AND ANSWERS
, 1
A client with myasthenia gravis becomes increasingly weak. The health care provider prepares to
identify whether the client is reacting to an overdose of the medication (cholinergic crisis) or
increasing severity of the disease (myasthenic crisis). An injection of edrophonium (Enlon) is
administered. Which of the following indicates that the client is in cholinergic crisis?
1. No change in the condition
2. Complaints of muscle spasms
3. An improvement of the weakness
4. A temporary worsening of the condition
Answer>4. A temporary worsening of the condition
Rationale:
An edrophonium (Enlon) injection, a cholinergic drug, makes the client in cholinergic crisis
temporarily worse. This is known as a negative test. An improvement of weakness would
occur if the client were experiencing myasthenia gravis. Options 1 and 2 would not occur in
either crisis.
2. Checking the frequency and consistency of bowel movements
Rationale:
The principal manifestations of Crohn's disease are diarrhea and abdominal pain. Infliximab
(Remicade) is an immunomodulator that reduces the degree of inflammation in the colon,
thereby reducing the diarrhea. Options 1, 3, and 4 are unrelated to this medication.
3. Liver enzyme levels
Rationale:
INH therapy can cause an elevation of hepatic enzyme levels and hepatitis. Therefore, liver
enzyme levels are monitored when therapy is initiated and during the first 3 months of
therapy. They may be monitored longer in the client who is greater than age 50 or abuses
alcohol.
4. Hypertension
Rationale:Cholinergic crisis occurs as a result of an overdose of medication. Indications of
cholinergic crisis include gastrointestinal disturbances, nausea, vomiting, diarrhea,
abdominal cramps, increased salivation and tearing, miosis, hypertension, sweating, and
increased bronchial secretions.
, 2
The client with squamous cell carcinoma of the larynx is receiving bleomycin intravenously. The
nurse caring for the client anticipates that which diagnostic study will be prescribed?
1. Echocardiography
2. Electrocardiography
3. Cervical radiography
4. Pulmonary function studies
2. Report yellow eyes or skin immediately.
Rationale:
INH is hepatotoxic, and therefore the client is taught to report signs and symptoms of
hepatitis immediately (which include yellow skin and sclera). For the same reason, alcohol
should be avoided during therapy. The client should avoid intake of Swiss cheese, fish such
as tuna, and foods containing tyramine because they may cause a reaction characterized
by redness and itching of the skin, flushing, sweating, tachycardia, headache, or
lightheadedness. The client can avoid developing peripheral neuritis by increasing the
intake of pyridoxine (vitamin B6) during the course of INH therapy for TB.
2. Calcium level
Rationale:
Tamoxifen may increase calcium, cholesterol, and triglyceride levels. Before the initiation
of therapy, a complete blood count, platelet count, and serum calcium levels should be
assessed. These blood levels, along with cholesterol and triglyceride levels, should be
monitored periodically during therapy. The nurse should assess for hypercalcemia while the
client is taking this medication. Signs of hypercalcemia include increased urine volume,
excessive thirst, nausea, vomiting, constipation, hypotonicity of muscles, and deep bone
and flank pain.
3. Reduction of steatorrhea
Rationale:
Pancrelipase (Pancrease MT) is a pancreatic enzyme used in clients with pancreatitis as a
digestive aid. The medication should reduce the amount of fatty stools (steatorrhea).
Another intended effect could be improved nutritional status. It is not used to treat
abdominal pain or heartburn. Its use could result in weight gain but should not result in
weight loss if it is aiding in digestion.
, 4. Pulmonary function studies
Rationale:
Bleomycin is an antineoplastic medication (Chemotheraputic Agents) that can cause
interstitial pneumonitis, which can progress to pulmonary fibrosis. Pulmonary function
studies along with hematological, hepatic, and renal function tests need to be monitored.
The nurse needs to monitor lung sounds for dyspnea and crackles, which indicate
pulmonary toxicity. The medication needs to be discontinued immediately if pulmonary
toxicity occurs. Options 1, 2, and 3 are unrelated to the specific use of this medication.
2025 LATEST TEST HESI PHARMACOLOGY (PHARM) EXAM
VERSION 1 (V1) COMPLETE ACCURATE REAL EXAM GRADED
A+ QUESTIONS AND ANSWERS
Bonie314 Stuvia
This Exam DocumentContains:
HESI PHARMACOLOGY
EXAM VERSION 1 (V1)
COMPLETE ACCURATE REAL EXAM
QUESTIONS AND ANSWERS
, 1
A client with myasthenia gravis becomes increasingly weak. The health care provider prepares to
identify whether the client is reacting to an overdose of the medication (cholinergic crisis) or
increasing severity of the disease (myasthenic crisis). An injection of edrophonium (Enlon) is
administered. Which of the following indicates that the client is in cholinergic crisis?
1. No change in the condition
2. Complaints of muscle spasms
3. An improvement of the weakness
4. A temporary worsening of the condition
Answer>4. A temporary worsening of the condition
Rationale:
An edrophonium (Enlon) injection, a cholinergic drug, makes the client in cholinergic crisis
temporarily worse. This is known as a negative test. An improvement of weakness would
occur if the client were experiencing myasthenia gravis. Options 1 and 2 would not occur in
either crisis.
2. Checking the frequency and consistency of bowel movements
Rationale:
The principal manifestations of Crohn's disease are diarrhea and abdominal pain. Infliximab
(Remicade) is an immunomodulator that reduces the degree of inflammation in the colon,
thereby reducing the diarrhea. Options 1, 3, and 4 are unrelated to this medication.
3. Liver enzyme levels
Rationale:
INH therapy can cause an elevation of hepatic enzyme levels and hepatitis. Therefore, liver
enzyme levels are monitored when therapy is initiated and during the first 3 months of
therapy. They may be monitored longer in the client who is greater than age 50 or abuses
alcohol.
4. Hypertension
Rationale:Cholinergic crisis occurs as a result of an overdose of medication. Indications of
cholinergic crisis include gastrointestinal disturbances, nausea, vomiting, diarrhea,
abdominal cramps, increased salivation and tearing, miosis, hypertension, sweating, and
increased bronchial secretions.
, 2
The client with squamous cell carcinoma of the larynx is receiving bleomycin intravenously. The
nurse caring for the client anticipates that which diagnostic study will be prescribed?
1. Echocardiography
2. Electrocardiography
3. Cervical radiography
4. Pulmonary function studies
2. Report yellow eyes or skin immediately.
Rationale:
INH is hepatotoxic, and therefore the client is taught to report signs and symptoms of
hepatitis immediately (which include yellow skin and sclera). For the same reason, alcohol
should be avoided during therapy. The client should avoid intake of Swiss cheese, fish such
as tuna, and foods containing tyramine because they may cause a reaction characterized
by redness and itching of the skin, flushing, sweating, tachycardia, headache, or
lightheadedness. The client can avoid developing peripheral neuritis by increasing the
intake of pyridoxine (vitamin B6) during the course of INH therapy for TB.
2. Calcium level
Rationale:
Tamoxifen may increase calcium, cholesterol, and triglyceride levels. Before the initiation
of therapy, a complete blood count, platelet count, and serum calcium levels should be
assessed. These blood levels, along with cholesterol and triglyceride levels, should be
monitored periodically during therapy. The nurse should assess for hypercalcemia while the
client is taking this medication. Signs of hypercalcemia include increased urine volume,
excessive thirst, nausea, vomiting, constipation, hypotonicity of muscles, and deep bone
and flank pain.
3. Reduction of steatorrhea
Rationale:
Pancrelipase (Pancrease MT) is a pancreatic enzyme used in clients with pancreatitis as a
digestive aid. The medication should reduce the amount of fatty stools (steatorrhea).
Another intended effect could be improved nutritional status. It is not used to treat
abdominal pain or heartburn. Its use could result in weight gain but should not result in
weight loss if it is aiding in digestion.
, 4. Pulmonary function studies
Rationale:
Bleomycin is an antineoplastic medication (Chemotheraputic Agents) that can cause
interstitial pneumonitis, which can progress to pulmonary fibrosis. Pulmonary function
studies along with hematological, hepatic, and renal function tests need to be monitored.
The nurse needs to monitor lung sounds for dyspnea and crackles, which indicate
pulmonary toxicity. The medication needs to be discontinued immediately if pulmonary
toxicity occurs. Options 1, 2, and 3 are unrelated to the specific use of this medication.
